Winlevi Adverse Reactions

Clinical Trials Experience: Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
In two identical multicenter, randomized, double-blind, vehicle-controlled trials, 1421 subjects 12 years and older with facial acne vulgaris applied WINLEVI cream or vehicle twice daily for 12 weeks. Overall, 62% of the subjects were female, and 38% were male, 91% of the patients were Caucasian, and the mean age was 19.7 years.
Local skin reactions (edema, erythema/redness, pruritus, scaling/dryness, skin atrophy, stinging/burning, striae rubrea, telangiectasia) were observed during the12-week treatment and occurred in a similar percentage of subjects treated with vehicle. Local skin reactions reported by ≥1% of subjects treated with WINLEVI cream are shown in the following table. (See Table 2.)

Click on icon to see table/diagram/image

The following adverse reactions associated with the use of WINLEVI cream were identified in clinical trials and long-term safety studies.
Metabolism: hyperkalemia [see Pharmacology: Pharmacodynamics under Actions].
Reproductive: polycystic ovaries, amenorrhea.